Menu
Search
|

Menu

Close
X

Co-Diagnostics Inc CODX.OQ (NASDAQ Stock Exchange Capital Market)

2.29 USD
+0.03 (+1.33%)
As of Nov 15
chart
Previous Close 2.26
Open 2.39
Volume 125
3m Avg Volume 7,390
Today’s High 2.44
Today’s Low 2.29
52 Week High 6.66
52 Week Low 1.45
Shares Outstanding (mil) 11.92
Market Capitalization (mil) 67.69
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.218
FY17
-0.612
FY16
-0.195
FY15
-0.051
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
--
5.95
Price to Book (MRQ)
vs sector
--
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
--
17.74
LT Debt to Equity (MRQ)
vs sector
--
13.15
Return on Investment (TTM)
vs sector
--
14.22
Return on Equity (TTM)
vs sector
--
15.99

EXECUTIVE LEADERSHIP

Dwight Egan
Chairman of the Board, President, Chief Executive Officer, Since 2013
Salary: $23,750.00
Bonus: --
Reed Benson
Chief Financial Officer, Secretary, Since 2017
Salary: --
Bonus: --
Brent Satterfield
Chief Science Officer, Director, Since 2013
Salary: $81,096.00
Bonus: --
Edward Borkowski
Independent Director, Since 2017
Salary: --
Bonus: --
Frank Kiesner
Independent Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4049 S Highland Dr
SALT LAKE CITY   UT   84124-1664

Phone: +1801.2789769

Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

SPONSORED STORIES